{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:02:28Z","timestamp":1777978948932,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"the key research and development project of hunan province","award":["2020SK2010"],"award-info":[{"award-number":["2020SK2010"]}]},{"DOI":"10.13039\/501100004735","name":"natural science foundation of\u00a0hunan province","doi-asserted-by":"publisher","award":["2020JJ5852"],"award-info":[{"award-number":["2020JJ5852"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["No. 81803639"],"award-info":[{"award-number":["No. 81803639"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s40121-021-00555-y","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T12:02:56Z","timestamp":1635854576000},"page":"175-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Study on Pharmacokinetic Interactions Between HS-10234 and Emtricitabine in Healthy Subjects: An Open-Label, Two-Sequence, Self-Controlled Phase I Trial"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04477096","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yeping","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6711-4251","authenticated-orcid":false,"given":"Qi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,30]]},"reference":[{"key":"555_CR1","unstructured":"World Health Organization. HIV\/AIDS. 2020; Accessed 10 July 2021."},{"key":"555_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119451","volume":"31","author":"M Sheykhhasan","year":"2021","unstructured":"Sheykhhasan M, Foroutan A, Manoochehri H, Khoei SG, Poondla N, Saidijam M. Could gene therapy cure HIV? Life Sci. 2021;31: 119451. https:\/\/doi.org\/10.1016\/j.lfs.2021.119451.","journal-title":"Life Sci"},{"issue":"1","key":"555_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003161","volume":"9","author":"P Mohammadi","year":"2013","unstructured":"Mohammadi P, Desfarges S, Bartha I, Joos B, Zangger N, Mu\u00f1oz M, G\u00fcnthard HF, Beerenwinkel N, Telenti A, Ciuffi A. 24 hours in the life of HIV-1 in a T cell line. PLoS Pathog. 2013;9(1): e1003161. https:\/\/doi.org\/10.1371\/journal.ppat.1003161.","journal-title":"PLoS Pathog"},{"issue":"6","key":"555_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nm0696-625","volume":"2","author":"MS Saag","year":"1996","unstructured":"Saag MS, Holodniy M, Kuritzkes DR, O\u2019Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA. HIV viral load markers in clinical practice. Nat Med. 1996;2(6):625\u20139. https:\/\/doi.org\/10.1038\/nm0696-625.","journal-title":"Nat Med"},{"key":"555_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab160","author":"LSM Huang","year":"2021","unstructured":"Huang LSM, Snyder EY, Schooley RT. Strategies and progress in CXCR4-targeted anti-HIV therapeutic development. Clin Infect Dis. 2021. https:\/\/doi.org\/10.1093\/cid\/ciab160.","journal-title":"Clin Infect Dis"},{"key":"555_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","volume":"18","author":"T Cihlar","year":"2016","unstructured":"Cihlar T, Fordyce M. Current status and prospects of HIV treatment. Curr Opin Virol. 2016;18:50\u20136. https:\/\/doi.org\/10.1016\/j.coviro.2016.03.004.","journal-title":"Curr Opin Virol"},{"key":"555_CR7","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: World Health Organization; 2016.","edition":"2"},{"issue":"11","key":"555_CR8","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1097\/QAD.0b013e328339fe53","volume":"24","author":"A Mocroft","year":"2010","unstructured":"Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD, EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24(11):1667\u201378. https:\/\/doi.org\/10.1097\/QAD.0b013e328339fe53.","journal-title":"AIDS"},{"issue":"12","key":"555_CR9","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1093\/infdis\/jir188","volume":"203","author":"GA McComsey","year":"2011","unstructured":"McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791\u2013801. https:\/\/doi.org\/10.1093\/infdis\/jir188.","journal-title":"J Infect Dis"},{"issue":"1","key":"555_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1124\/mol.108.045526","volume":"74","author":"G Birkus","year":"2008","unstructured":"Birkus G, Kutty N, He GX, Mulato A, Lee W, McDermott M, Cihlar T. Activation of 9-[(R)-2-[[(S)-[[(S)-1- (Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol. 2008;74(1):92\u2013100. https:\/\/doi.org\/10.1124\/mol.108.045526.","journal-title":"Mol Pharmacol"},{"issue":"2","key":"555_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1021\/mp3002045","volume":"10","author":"D Babusis","year":"2013","unstructured":"Babusis D, Phan TK, Lee WA, Watkins WJ, Ray AS. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm. 2013;10(2):459\u201366. https:\/\/doi.org\/10.1021\/mp3002045.","journal-title":"Mol Pharm"},{"issue":"4","key":"555_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","volume":"63","author":"PJ Ruane","year":"2013","unstructured":"Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, Zhong L, Ramanathan S, Rhee MS, Fordyce MW, Yale K. Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449\u201355. https:\/\/doi.org\/10.1097\/QAI.0b013e3182965d45.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"555_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/apt.16196","volume":"53","author":"H Zhang","year":"2021","unstructured":"Zhang H, Hu Y, Wu M, Liu J, Zhu X, Li X, Chen H, Li C, Liu C, Niu J, Ding Y. Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection. Aliment Pharmacol Ther. 2021;53(2):243\u201352. https:\/\/doi.org\/10.1111\/apt.16196.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"555_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","volume":"62","author":"K Agarwal","year":"2015","unstructured":"Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E, Zhao S, Subramanian GM, McHutchison JG, Gane EJ, Foster GR. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015;62(3):533\u201340. https:\/\/doi.org\/10.1016\/j.jhep.2014.10.035.","journal-title":"J Hepatol"},{"key":"555_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/0471142735.im0701s85","author":"IJ Fuss","year":"2009","unstructured":"Fuss IJ, Kanof ME, Smith PD, Zola H. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol. 2009. https:\/\/doi.org\/10.1002\/0471142735.im0701s85 (Chapter 7:Unit7.1).","journal-title":"Curr Protoc Immunol"},{"key":"555_CR16","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Bioanalytical method validation: guidance for industry. 2018. Accessed 10 July 2021."},{"issue":"5","key":"555_CR17","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/jac\/dkt532","volume":"69","author":"M Markowitz","year":"2014","unstructured":"Markowitz M, Zolopa A, Squires K, Ruane P, Coakley D, Kearney B, Zhong L, Wulfsohn M, Miller MD, Lee WA. Phase I\/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother. 2014;69(5):1362\u20139. https:\/\/doi.org\/10.1093\/jac\/dkt532.","journal-title":"J Antimicrob Chemother"},{"key":"555_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","volume":"125","author":"AS Ray","year":"2016","unstructured":"Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human immunodeficiency virus. Antivir Res. 2016;125:63\u201370. https:\/\/doi.org\/10.1016\/j.antiviral.2015.11.009 (Epub 2015 Nov 27).","journal-title":"Antivir Res"},{"issue":"22","key":"555_CR19","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.2165\/00003495-200363220-00003","volume":"63","author":"LM Bang","year":"2003","unstructured":"Bang LM, Scott LJ. Emtricitabine: an antiretroviral agent for HIV infection. Drugs. 2003;63(22):2413\u201324. https:\/\/doi.org\/10.2165\/00003495-200363220-00003 (discussion 2425-6).","journal-title":"Drugs"},{"issue":"5","key":"555_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00280-020-04154-5","volume":"86","author":"A Joshi","year":"2020","unstructured":"Joshi A, Kiesel BF, Chaphekar N, Jones R, Guo J, Kunos CA, Taylor S, Chu E, Venkataramanan R, Beumer JH. In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine. Cancer Chemother Pharmacol. 2020;86(5):633\u201340. https:\/\/doi.org\/10.1007\/s00280-020-04154-5 (Epub 2020 Sep 28).","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"555_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/QAI.0000000000001699","volume":"78","author":"R Begley","year":"2018","unstructured":"Begley R, Das M, Zhong L, Ling J, Kearney BP, Custodio JM. Pharmacokinetics of tenofovir alafenamide when coadministered with other HIV antiretrovirals. J Acquir Immune Defic Syndr. 2018;78(4):465\u201372. https:\/\/doi.org\/10.1097\/QAI.0000000000001699.","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00555-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-021-00555-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00555-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T17:33:31Z","timestamp":1644946411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-021-00555-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,30]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1007\/s40121-021-00555-y","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,30]]},"assertion":[{"value":"7 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}